Wessel Due F

General characteristics. Structure:

Active ingredient: 600 LE sulodeksid.

Excipients: sodium chloride, water for injections.

* - lipoproteinlipazny unit.

Pharmacological properties:

Pharmacodynamics. Wessel Due F (сулодексид) is the natural product extracted and allocated from a mucous membrane of a small intestine of a pig. Represents natural mix of glikozaminoglikan (EIDERS): geparinopodobny fraction with a molecular weight of 8 000 дальтон (80%) and a dermatansulfata (20%).

The mechanism of action of a sulodeksid is caused by two main properties: the high-speed geparinopodobny fraction has affinity to antithrombin III (ATIII), and dermatanovy - to a cofactor of the II heparin (KGII).

Pharmacological action: anticoagulating, angioprotektivny, pro-fibrinolitic, antitrombotichesky.

Anti-coagulative action is shown due to affinity to a cofactor of the II heparin which inactivates thrombin.

The mechanism of antitrombotichesky action is connected with suppression of the activated X factor, with strengthening of synthesis and secretion of prostacyclin (PGI2), with decrease in level of fibrinogen in a blood plasma.

Pro-fibrinolitic actions it is caused by increase in blood of level of a fabric plasminogen activator and decrease in content of its inhibitor.

Angioprotektivny action is connected with recovery of structural and functional integrity of cells of an endothelium of vessels, with recovery of normal density of negative electric charge of a time of a basal membrane of vessels. Besides, drug normalizes rheological properties of blood due to decrease in level of triglycerides (stimulates lipolytic enzyme - the lipoproteinlipase hydrolyzing triglycerides, LPNP which is a part).

Efficiency of use of drug at a diabetic nephropathy is defined by ability of a sulodeksid to reduce thickness of a basal membrane and products of an extracellular matrix due to decrease in proliferation of cells of a mesangium.

Pharmacokinetics. 90% of a sulodeksid are absorbed in an endothelium of vessels that exceeds its concentration in fabrics of other bodies at 20-30 times and is soaked up in a small intestine. It is metabolized in a liver and kidneys. Unlike unfractionated heparin and low-molecular heparins, сулодексид is not exposed to a desulfatirovaniye which leads to decrease in antitrombotichesky activity and considerably accelerates elimination from an organism. Distribution of a dose on bodies showed that drug is metabolized and removed by kidneys in 4 hours after introduction.

In 24 hours after intravenous administration of drug excretion with urine makes 50% of connection, and in 48 hours - 67%.

Indications to use:

- angiopatiya with the increased risk of a thrombogenesis, including after the postponed myocardial infarction;
- disturbance of cerebral circulation, including the acute period of an ischemic stroke and the period of early recovery; the distsirkulyatorny encephalopathy caused by atherosclerosis, a diabetes mellitus, an idiopathic hypertensia; vascular dementia;
- occlusal damages of peripheral arteries of both atherosclerotic, and diabetic genesis;
- flebopatiya, deep vein thrombosis;
- mikroangiopatiya (a nephropathy, a retinopathy, neuropathy) and a macrovascular disease at a diabetes mellitus (a syndrome of diabetic foot, encephalopathy, a cardiopathy);
- trombofilichesky states, an anti-phospholipidic syndrome (appoint together with acetylsalicylic acid, and also after low-molecular heparins);
- treatment of geparinindutsirovanny trombotichesky thrombocytopenia as does not cause and does not aggravate it.

Route of administration and doses:

Treatment begins with daily intramuscular introduction of contents of 1 ampoule of drug or intravenous administration bolyusno or kapelno, previously having dissolved in 150 - 200 ml of normal saline solution, within 15-20 days. Then, within 30-40 days, therapy should be continued, accepting drug inside: appoint on 1 capsule 2 times a day in a break between meals. It is necessary to repeat a full course of treatment not less than 2 times a year.

Depending on results of clinicodiagnostic inspection of the patient, at the discretion of the doctor the mode of dosing can be changed.

Features of use:

Use during pregnancy and a lactation. At pregnancy it is appointed under strict observation of the doctor. There is a positive experience of use of drug сулодексид for the purpose of treatment and prevention of vascular complications for patients with diabetes like I in II and III trimesters pregnancy, at development of late toxicosis of pregnant women.

At use of drug control of a koagulogramma is necessary. At the beginning and the end of treatment it is reasonable to define the following indicators: the activated partial tromboplatinovy time, antithrombin III, a bleeding time and time of coagulation. Wessel Due F increases normal indicators the activated partial tromboplastinovy time, approximately by one and a half times.

Influence on ability to drive the car or other mechanisms. Drug does not influence ability of driving of the car and control of the machine equipment.

Side effects:

From a GIT: nausea, vomiting, pains in epigastriums.

Allergic reactions: skin rash of various localization.

Others: pain, burning, a hematoma in the place of an injection.

Interaction with other medicines:

Significant interaction of drug of Wessel Due F with other drugs it is not established.

At use of a sulodeksid it is not recommended to use at the same time the drugs influencing system of a hemostasis as anticoagulants (direct and indirect) and antiagregant.

Contraindications:

- hypersensitivity;
- the hemorrhagic diathesis and diseases which are followed by the lowered coagulability of blood;
- pregnancy I trimester.

Overdose:

Symptoms: bleeding or bleeding.

Treatment: drug withdrawal, symptomatic therapy.

Storage conditions:

List B. At a temperature not above 30 °C. To store in the place, unavailable to children! A period of validity - 5 years. Not to use after the specified period of validity.

Issue conditions:

According to the recipe

Packaging:

Solution for intravenous and intramuscular administration: 600 LIE/2 ml in ampoules: on 5 ampoules in each of 2-circuit strip packagings or 10 ampoules in 1 blister strip packaging with the application instruction in a pack cardboard.